cas 2199-51-1|| where to buy ethyl 2,4-dimethyl-1H-pyrrole-3-carboxylate

Product Name:ethyl 2,4-dimethyl-1H-pyrrole-3-carboxylate

IUPAC Name:ethyl 2,4-dimethyl-1H-pyrrole-3-carboxylate

Packing Unit	Available Stock	Price($)
CM103853-25g	in stock	ƴŸ
CM103853-100g	in stock	Ȥœœ
CM103853-500g	in stock	œǠƚƚ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Additional Notes

Verification code*

refresh

: CAS NO:2199-51-1; Molecular Formula:C9H13NO2; Melting Point:-; Smiles Code:CCOC(=O)C1=C(C)NC=C1C; Density:

: Catalog Number:CM103853; Molecular Weight:167.21; Boiling Point:291°C at 760 mmHg; MDL No:MFCD01365811; Storage:Store at room temperature

: Pyrroles; Pyrrole is a five membered heterocyclic compound with the molecular formula of C4H5N. Pyrrole has a ring composed of four carbon atoms and one nitrogen atom. Pyrrole is easy to polymerize in the air. Pyrrole is the parent compound of many important biological substances (such as bile pigment, porphyrin and chlorophyll). Pyrrole scaffolds are widely used in biological and pharmaceutical fields. Pyrrole is a special heterocyclic scaffold, which exists in many natural products, drug molecules and pesticides, and has shown its application in materials science.; Pyrrole,Where to Buy Pyrroles-Chemenu; Pyrrole,Where to Buy Pyrroles; Pyrrole is a heterocyclic, aromatic, organic compound, a five-membered ring with the formula C 4H 4NH. It is a colorless volatile liquid that darkens readily upon exposure to air. Substituted derivatives are also called pyrroles, e.g., N-methylpyrrole.

: Vorolanib; EyePoint Pharmaceuticals announced on December 4th announced positive topline results of its Phase 2 DAVIO 2 trial of EYP-1901, an investigational sustained delivery maintenance treatment for wet age-related macular degeneration (wet AMD) combining vorolanib, a selective tyrosine kinase inhibitor with bioerodible Durasert E™. Vorolanib brings a new mechanistic approach to the treatment of VEGF-mediated retinal diseases as a pan-VEGF receptor blocker, blocking all VEGF isoforms. Vorolanib features reduced off-target binding and at clinically relevant doses does not inhibit Tie-2, a critical pathway associated with vascular stability, which may result in an improved efficacy. Further, in an in-vivo model of retinal detachment, vorolanib demonstrated neuroprotection, and potential antifibrotic benefits.